Medplus Health Services Limited

BSE: MEDPLUS543427ISIN INE804L01022

Consumer Discretionary
Pharmacy Retail
BSE 500

BSE listing

Share price

₹659.50+5.45 (+0.83%)

as of 18 Sep 2026

52W high: ₹1,020.35
52W low: ₹645.25
Off 52W high: -35.37%
1M return: +1.48%
3M return: -21.89%
6M return: -19.68%
1Y return: -21.09%
20D avg volume: 21,323
50 DMA: ₹700.18
200 DMA: ₹807.95

Key ratios Consolidated

Market cap: ₹7,923 Cr
Current price: ₹659.50
52W high / low: ₹1,020.35 / ₹645.25
Face value: ₹2.00
P/E: 37.65
P/B: —
EPS (TTM): ₹17.52
Book value / share: —
ROE: —
ROCE: 12.20%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-198.41 Cr
Interest cover: 3.29
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 58.3 days

About

In plain English

MedPlus runs a large chain of retail pharmacies across India, like the neighborhood drugstore but on a massive scale. You walk into one of their stores to buy prescription medicines, over-the-counter drugs, and personal care items like soaps and vitamins. They also sell their own private-label products, which are cheaper alternatives to big brands—think store-brand pain relievers. Beyond the pharmacy, MedPlus offers diagnostic services like blood tests through its own labs and collection centers. Their customers are everyday people, but they also franchise stores to local operators and sell to other businesses. MedPlus makes money by earning a margin on every product sold, plus fees from franchisees and diagnostic test charges.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 21 Jul 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	1,880	1,864	1,806	1,679	1,543	1,510	1,561	1,576	1,489	1,490	1,441	1,409
	19.83	20.59	18.24	17.47	15.02	15.79	12.52	11.60	8.71	10.46	9.79	10.37
	1,858	1,805	1,751	1,628	1,505	1,464	1,517	1,540	1,480	1,469	1,431	1,403
	20.66	25.62	20.52	23.41	19.18	19.55	14.24	15.55	12.38	12.24	12.54	9.84
	1,459	1,395	1,362	1,221	1,053	1,137	1,107	1,083	1,246	1,163	1,152	1,180
	241.91	238.12	232.65	213.32	200.44	194.17	189.68	180.34	161.82	160.60	159.53	157.79
	33.27	33.48	30.83	28.82	27.36	26.84	25.97	25.12	24.66	25.13	24.50	23.54
	77.92	75.95	72.74	68.56	65.62	64.21	62.47	63.13	60.03	59.22	57.11	55.47
	85.16	86.15	81.18	76.91	71.73	70.43	68.66	69.52	73.67	70.13	67.42	61.61
	41.88	80.34	73.29	68.94	52.77	61.12	56.60	47.78	17.79	31.98	19.96	16.44
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	41.88	80.34	73.29	68.94	52.77	61.12	56.60	47.78	17.79	31.98	19.96	16.44
	8.71	16.37	15.50	13.43	10.42	9.80	10.73	9.09	3.44	1.58	6.26	1.90
	33.17	63.97	57.79	55.50	42.34	51.32	45.87	38.70	14.34	33.56	13.71	14.54
	2.76	5.33	4.82	4.63	3.54	4.32	3.84	3.24	1.20	2.81	1.15	1.22
Key metrics
	153.07	189.77	176.86	166.32	145.75	152.17	145.04	136.03	102.48	116.33	101.57	95.45
	8.10%	10.20%	9.80%	9.90%	9.40%	10.10%	9.30%	8.60%	6.90%	7.80%	7.00%	6.80%
	1.80%	3.40%	3.20%	3.30%	2.70%	3.40%	2.90%	2.50%	1.00%	2.30%	1.00%	1.00%
	—	3.50%	—	3.40%	—	3.20%	—	—	—	—	—	—
	21.80%	23.50%	15.70%	6.50%	3.60%	1.30%	8.30%	11.90%	—	—	—	—
	-21.70%	24.60%	26.00%	43.40%	195.30%	52.90%	234.60%	166.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	7,229	6,892	6,136	5,625	4,558	3,779
	76.13	71.32	48.62	40.01	46.08	31.36
	7,041	6,688	6,001	5,591	4,556	3,693
	90.21	88.73	61.72	44.53	25.88	19.44
	5,437	5,030	4,572	4,538	3,753	3,122
	926.00	884.53	726.02	625.52	545.13	393.92
	126.40	120.49	102.59	96.43	83.03	66.43
	295.17	282.87	249.84	224.21	181.56	119.36
	329.40	315.96	282.27	253.63	189.09	130.62
	264.45	275.33	183.29	73.44	47.16	117.94
	0.00	0.00	0.00	0.00	0.00	0.00
	264.45	275.33	183.29	73.44	47.16	117.94
	54.01	55.72	33.06	7.87	2.94	23.23
	210.43	219.61	150.23	65.58	50.10	94.72
	17.54	18.33	12.57	5.48	4.17	8.55
Key metrics
	686.02	678.69	535.72	394.08	311.75	303.73
	9.49%	9.80%	8.70%	7.00%	6.80%	8.00%
	2.91%	3.20%	2.40%	1.20%	1.10%	2.50%
	—	12.20%	10.30%	—	—	—
	—	12.30%	9.10%	23.40%	20.60%	—
	—	46.20%	129.10%	30.90%	-47.10%	—
	—	372.55	480.98	—	—	—
	—	2.26	3.60	—	—	—
	—	0.00	0.00	—	—	—
	—	-198.41	-86.05	—	—	—
	—	58.3	63.0	—	—	—
Balance sheet
	—	3,933	3,360	—	—	—
	—	2,069	1,844	—	—	—
	—	198.41	86.05	—	—	—
	—	26.96	13.27	—	—	—
	—	1,382	1,345	—	—	—
	—	—	36.48	—	—	—
	—	318.36	290.67	—	—	—
	—	306.95	298.96	—	—	—
	—	689.29	576.59	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	1,975	1,740	—	—	—
Cash flow
	—	495.58	540.43	—	—	—
	—	-127.72	-317.61	—	—	—
	—	-255.50	-227.98	—	—	—
	—	123.03	59.45	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	222.64	248.04	223.00	205.65	183.88	201.75	176.79	156.23	178.33	148.37	148.10	98.67
	3.27	2.49	2.70	2.94	2.65	2.65	2.19	2.25	1.84	1.90	1.82	1.76
	202.89	227.47	203.87	187.97	168.85	186.49	166.95	148.84	168.56	143.94	145.68	100.48
	18.92	18.14	20.52	23.41	19.18	19.55	14.24	15.45	12.38	11.97	12.54	10.12
	149.62	173.63	147.83	131.41	117.52	137.20	121.25	101.06	126.52	101.07	101.57	62.53
	13.72	14.71	14.06	13.26	12.26	12.00	12.14	11.84	11.23	11.68	11.29	10.88
	2.22	1.40	2.40	2.37	2.15	2.08	2.35	2.09	2.10	2.11	2.10	2.11
	6.96	5.43	7.19	7.04	6.72	6.51	6.50	7.47	6.47	6.40	6.27	5.96
	11.95	14.02	11.41	10.87	10.51	10.24	10.61	11.02	9.64	11.35	10.90	9.60
	23.02	23.06	21.83	20.61	17.68	17.91	12.03	9.64	11.61	6.32	4.24	-0.04
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	23.02	23.06	21.83	20.61	17.68	17.91	12.03	9.64	11.61	6.32	4.24	-0.04
	5.57	6.38	5.25	4.98	4.14	3.93	2.66	1.89	2.35	3.59	1.05	—
	17.45	16.67	16.58	15.63	13.53	13.98	9.37	7.75	9.26	9.92	3.19	-0.04
	1.45	1.39	1.38	1.31	1.13	1.17	0.78	0.65	0.77	0.83	0.27	0.05
Key metrics
	32.20	29.89	31.42	30.02	26.55	26.50	20.88	19.20	20.18	14.83	12.61	8.03
	14.50%	12.10%	14.10%	14.60%	14.40%	13.10%	11.80%	12.30%	11.30%	10.00%	8.50%	8.10%
	7.80%	6.70%	7.40%	7.60%	7.40%	6.90%	5.30%	5.00%	5.20%	6.70%	2.20%	0.00%
	—	1.70%	—	1.70%	—	1.50%	—	—	—	—	—	—
	21.10%	22.90%	26.10%	31.60%	3.10%	36.00%	19.40%	58.30%	—	—	—	—
	29.00%	19.20%	76.90%	101.70%	46.10%	40.90%	193.70%	19,475.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	899.33	860.57	713.10	467.03	213.93	145.71
	11.40	10.77	8.94	7.29	16.24	9.54
	822.20	788.16	670.86	467.28	222.58	149.68
	80.99	81.24	61.62	44.52	25.78	19.36
	602.49	570.38	486.02	307.39	131.49	97.21
	55.75	54.30	47.22	43.61	28.14	13.73
	8.39	8.31	8.62	8.40	6.54	2.63
	26.62	26.39	26.94	24.17	15.31	4.63
	48.25	46.81	41.52	40.07	22.65	10.11
	88.52	83.17	51.17	7.04	7.59	5.58
	0.00	0.00	0.00	—	—	—
	88.52	83.17	51.17	7.04	7.59	5.58
	22.18	20.76	10.84	2.54	2.04	—
	66.33	62.41	40.34	9.58	5.54	5.58
	5.53	5.21	3.37	0.80	0.46	0.50
Key metrics
	123.53	117.87	86.73	39.61	29.44	12.84
	13.74%	13.70%	12.20%	8.50%	13.80%	8.80%
	7.38%	7.30%	5.70%	2.10%	2.60%	3.80%
	—	6.50%	4.50%	—	—	—
	—	20.70%	52.70%	118.30%	46.80%	—
	—	54.70%	321.10%	72.90%	-0.70%	—
	—	55.92	37.44	—	—	—
	—	0.99	1.16	—	—	—
	—	0.00	0.00	—	—	—
	—	-46.45	-11.30	—	—	—
	—	53.2	48.6	—	—	—
Balance sheet
	—	1,465	1,399	—	—	—
	—	355.15	275.27	—	—	—
	—	46.45	11.30	—	—	—
	—	132.61	121.62	—	—	—
	—	26.77	18.32	—	—	—
	—	9.66	9.43	—	—	—
	—	91.10	100.72	—	—	—
	—	34.03	45.16	—	—	—
	—	63.50	68.80	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	1,316	1,240	—	—	—
Cash flow
	—	61.98	46.68	—	—	—
	—	-22.03	-39.19	—	—	—
	—	-4.79	-9.91	—	—	—
	—	6.06	9.24	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +59.04%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: +124.17%
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): +25.14%
Profit YoY (TTM): +48.62%

Consolidated

Sales CAGR 3Y: +14.78%
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: +63.66%
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): +16.79%
Profit YoY (TTM): +18.07%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 40.19%

Holder	Type	Holding	Previous	Change
LONE FURROW INVESTMENTS PRIVATE LIMITED	Promoter	14.38%	—	—
AGILEMED INVESTMENTS PRIVATE LIMITED	Promoter	13.03%	—	—
MADHUKAR REDDY GANGADI	Promoter	12.78%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA	Public	7.32%	—	—
ICICI PRUDENTIAL PHARMA HEALTHCARE AND DIAGANOSTIC	Public	4.93%	—	—
FRANKLIN INDIA FLEXI CAP FUND	Public	3.90%	—	—
SBI ELSS TAX SAVER FUND	Public	3.39%	—	—
KOTAK SMALL CAP FUND	Public	3.31%	—	—
FIDELITY FUNDS - INDIA FOCUS FUND	Public	1.68%	—	—
KUWAIT INVESTMENT AUTHORITY FUND 227	Public	1.55%	—	—
PRAVESA HOLDING PRIVATE LIMITED	Public	1.51%	—	—
HDFC LIFE INSURANCE COMPANY LIMITED	Public	1.22%	—	—
BAJAJ LIFE INSURANCE LIMITED	Public	1.03%	—	—
RENUKA GANGADI	Promoter Group	0.00%	—	—
RAJITHA KOPPULA REDDY	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Board comments on fine levied by the Exchange10 Sep 2026 · Company Update / General
Outcome of Board meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)10 Sep 2026 · Others / Outcome without intimation
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August ....26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2026 for Agilemed Investments Pvt Ltd26 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd21 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund21 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Submission of Voting results Along with Scrutinizer''s Report of the 20th Annual General Meeting of the company.18 Aug 2026 · AGM/EGM / AGM
Summary Proceedings of 20th Annual General Meeting of the Company held on August 17, 202617 Aug 2026 · AGM/EGM / AGM
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20156 Aug 2026 · Company Update / General
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 20155 Aug 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd1 Aug 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201531 Jul 2026 · Company Update / General
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July ....29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July ....29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Lone Furrow Investment Pvt Ltd29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Agilemed Investments Pvt Ltd29 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd28 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Submission of Transcript of Earnings Call24 Jul 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication - for completion of dispatch of Notice of 20th Annual General Meeting.24 Jul 2026 · Company Update / Newspaper Publication
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201524 Jul 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund24 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
BRSR for F.Y. 2025-2623 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Notice of 20th AGM of the Company for the F.Y.2025-2623 Jul 2026 · AGM/EGM / AGM
20th Annual Report of the Company for the Financial Year 2025-26 along with Notice to the Shareholders for Annual General Meeting23 Jul 2026 · Others / Reg. 34 (1) Annual Report
Outcome of the Board meeting23 Jul 2026 · Others / Outcome without intimation
Request to Ignore Inadvertent Filing of Investor Presentation22 Jul 2026 · Company Update / General
Request to ignore Inadvertent Filing of Investor Presentation.22 Jul 2026 · Company Update / General
Request to Ignore Inadvertent Filing of Investor Presentation.22 Jul 2026 · Company Update / General
Request to Ignore Inadvertent Filing of Investor Presentation22 Jul 2026 · Company Update / General
Request to Ignore Inadvertent Filing of Investor Presentation22 Jul 2026 · Company Update / General
Submission of Audio Recordings of Earnings Call22 Jul 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication - Information regarding the 20th Annual general Meeting of the Company to be held on August 17, 2026 through Video Conferencing/ Other Audio Visual Means22 Jul 2026 · Company Update / Newspaper Publication
Submission of Newspaper Clippings22 Jul 2026 · Company Update / Newspaper Publication
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201522 Jul 2026 · Company Update / General
Presentation for Earnings Call with Analysts/Instituitional Investors on Un-Audited Financials Results for the quater ended June 30, 202621 Jul 2026 · Company Update / Investor Presentation
Intimation of Investor Presentation21 Jul 2026 · Company Update / Investor Presentation
Intimation of Appointment of Company Secretary and Compliance Officer21 Jul 2026 · Company Update / Appointment of Company Secretary / Compliance Officer
Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)21 Jul 2026 · Result / Financial Results
Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)21 Jul 2026 · Board Meeting / Outcome of Board Meeting
Schedule of Analysts or Institutional Investors Meet - Earnings Call with respect to audited Financial Results of the Company for the quarter ended June 30, 202615 Jul 2026 · Company Update / Analyst / Investor Meet